|

UAE Inhibitor TAK-243 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: AOB87172, MLN7243, TAK-243

Pipeline

Phase 1: 2

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Cancer2
  • Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia1
  • Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia1
  • Myelodysplastic Syndrome With Excess Blasts1
  • Refractory Myelodysplastic Syndrome1

Tampa, Florida1 trial

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Moffitt Cancer Center

Phase 1

Bethesda, Maryland1 trial

Studying TAK-243 in Patients With Advanced Cancer

National Cancer Institute Developmental Therapeutics Clinic

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.